Shots: The P-III QuANTUM-First trial evaluates quizartinib vs placebo in combination with standard induction and consolidation CT & continued with quizartinib as monothx. in a ratio (1:1) in 539 patients […]readmore
Shots: The P-III PROVENT & TACKLE trial evaluates AZD7442 (IM) vs PBO in a ratio (2:1) & (1:1) in 5197 & 903 patients with COVID-19 In the PROVENT trial, AZD7442 […]readmore
Shots: The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in non-hospitalized adult patients with COVID-19 with 1 risk factor associated with poor disease outcomes & symptom onset within 5 days […]readmore
Shots: The P-III trial evaluates arpraziquantel in patients aged 3mos. to 6yrs. with schistosomiasis who are infected with S. mansoni or S. haematobium The trial has met its 1EPs i.e., […]readmore
Shots: The new analysis from the clinical trial data evaluates Livmarli (IBAT inhibitor) vs natural history cohort in patients with alagille syndrome. The extensive real-world analysis conducted by GALA & […]readmore
Shots: The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO […]readmore
Shots: The P-II AXIOMATIC-TKR study evaluates the efficacy and safety of milvexian (qd/bid) vs enoxaparin (SC) in 1242 patients with elective TKR surgery The trial met both of its pre-specified […]readmore
Shots: The P-Ib clinical trial evaluates the safety & tolerability of IBI302 multi-intravitreal injection in 18 patients with nAMD The results showed an improvement in visual acuity & reduction in […]readmore
Shots: The ongoing P-II AAVIATE & ALTITUDE trial evaluates RGX-314 using suprachoroidal delivery in patients with wet AMD & DR without CI-DME, respectively In the P-II AAVIATE trial, the therapy […]readmore
Shots: The P-III COMET-TAIL trial evaluates the efficacy, safety & tolerability of sotrovimab (250/500mg, given as IM compared to IV) in 983 high-risk patients aged ≥12yrs. with COVID-19 for 7 […]readmore